{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:22:24Z","timestamp":1740144144358,"version":"3.37.3"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T00:00:00Z","timestamp":1558483200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T00:00:00Z","timestamp":1558483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP26460857"],"award-info":[{"award-number":["JP26460857"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["H28-IRYO-SHITEI-020"],"award-info":[{"award-number":["H28-IRYO-SHITEI-020"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s40264-019-00833-2","type":"journal-article","created":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T23:17:07Z","timestamp":1558567027000},"page":"1055-1069","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Auto-Generated Physiological Chain Data for an Ontological Framework for Pharmacology and Mechanism of Action to Determine Suspected Drugs in Cases of Dysuria"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3479-115X","authenticated-orcid":false,"given":"Masayo","family":"Hayakawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Imai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimasa","family":"Kawazoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouji","family":"Kozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Ohe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,22]]},"reference":[{"key":"833_CR1","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/j.1447-0594.2005.00313.x","volume":"5","author":"H Arai","year":"2005","unstructured":"Arai H, Akishita M, Teramoto S, Mizukami K, Morimoto S, Toba K. Incidence of adverse drug reactions in geriatric units of university hospitals. Geriatr Gerontol Int. 2005;5:293\u20137.","journal-title":"Geriatr Gerontol Int."},{"key":"833_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1447-0594.2010.00631.x","volume":"11","author":"M Akishita","year":"2011","unstructured":"Akishita M, Arai H, Arai H, Inamatsu T, Kuzuya M, Suzuki Y, et al. Survey on geriatricians\u2019 experiences of adverse drug reactions caused by potentially inappropriate medications: Commission report of the Japan Geriatrics Society. Geriatr Gerontol Int. 2011;11:3\u20137.","journal-title":"Geriatr Gerontol Int"},{"key":"833_CR3","first-page":"1","volume":"38","author":"I Oosterhuis","year":"2018","unstructured":"Oosterhuis I, Zweers P, R\u00fcmke H, Muller-Hansma A, van Puijenbroek EP. A tailor-made approach for causality assessment for ADR reports on drugs and vaccines. Pharmacoepidemiol Drug Saf. 2018;38:1\u20137.","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"833_CR4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1126\/science.1158140","volume":"321","author":"M Campillos","year":"2008","unstructured":"Campillos M, Kuhn M, Gavin A-C, Jensen LJ, Bork P. Drug target identification using side-effect similarity. Science (80-). 2008;321:263\u20136.","journal-title":"Science (80-)"},{"key":"833_CR5","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1517\/17425255.2010.509343","volume":"6","author":"R Garcia-Serna","year":"2010","unstructured":"Garcia-Serna R, Mestres J. Anticipating drug side effects by comparative pharmacology. Expert Opin Drug Metab Toxicol. 2010;6:1253\u201363.","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"833_CR6","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/1471-2105-11-255","volume":"11","author":"B Chen","year":"2010","unstructured":"Chen B, Dong X, Jiao D, Wang H, Zhu Q, Ding Y, et al. Chem2Bio2RDF: a semantic framework for linking and data mining chemogenomic and systems chemical biology data. BMC Bioinform. 2010;11:255.","journal-title":"BMC Bioinform."},{"key":"833_CR7","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s40264-016-0414-0","volume":"39","author":"S Sarntivijai","year":"2016","unstructured":"Sarntivijai S, Zhang S, Jagannathan DG, Zaman S, Burkhart KK, Omenn GS, et al. Linking MedDRA-coded clinical phenotypes to biological mechanisms by the ontology of adverse events : a pilot study on tyrosine kinase inhibitors. Drug Saf. 2016;39:697\u2013707.","journal-title":"Drug Saf."},{"key":"833_CR8","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/wsbm.114","volume":"3","author":"SI Berger","year":"2011","unstructured":"Berger SI, Iyengar R. Role of systems pharmacology in understanding drug adverse events. Wiley Interdiscip Rev Syst Biol Med. 2011;3:129\u201335.","journal-title":"Wiley Interdiscip Rev Syst Biol Med."},{"key":"833_CR9","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.chembiol.2013.03.017","volume":"20","author":"M Duran-Frigola","year":"2013","unstructured":"Duran-Frigola M, Aloy P. Analysis of chemical and biological features yields mechanistic insights into drug side effects. Chem Biol. 2013;20:594\u2013603.","journal-title":"Chem Biol"},{"key":"833_CR10","unstructured":"Sider 2 [Internet]. 2015. \n                    http:\/\/sideeffects.embl.de\/\n                    \n                  . Accessed 13 Mar 2015."},{"key":"833_CR11","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/msb.2009.98","volume":"6","author":"M Kuhn","year":"2010","unstructured":"Kuhn M, Campillos M, Letunic I, Jensen LJ, Bork P. A side effect resource to capture phenotypic effects of drugs. Mol Syst Biol. 2010;6:343.","journal-title":"Mol Syst Biol."},{"key":"833_CR12","unstructured":"Canadian Institutes of Health Research. DrugBank [Internet]. 2015. \n                    http:\/\/www.drugbank.ca\/\n                    \n                  . Accessed 8 Dec 2018."},{"key":"833_CR13","doi-asserted-by":"publisher","first-page":"D901","DOI":"10.1093\/nar\/gkm958","volume":"36","author":"DS Wishart","year":"2008","unstructured":"Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008;36:D901\u20136.","journal-title":"Nucleic Acids Res."},{"key":"833_CR14","unstructured":"Stanford University. PharmGKB [Internet]. 2015. \n                    http:\/\/www.pharmgkb.org\/\n                    \n                  . Accessed 13 Mar 2015."},{"key":"833_CR15","doi-asserted-by":"publisher","first-page":"795","DOI":"10.2217\/bmm.11.94","volume":"5","author":"EM McDonagh","year":"2011","unstructured":"McDonagh EM, Whirl-Carrillo M, Garten Y, Altman RB, Klein TE. From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource. Biomark. Med. 2011;5:795\u2013806.","journal-title":"Biomark. Med."},{"key":"833_CR16","unstructured":"U.S. Department of Veterans Affair. National Drug File Reference Terminology (NDF-RT) [Internet]. \n                    http:\/\/www.va.gov\/\n                    \n                  . Accessed 13 Mar 2015."},{"key":"833_CR17","first-page":"391","volume":"107","author":"MJ Lincoln","year":"2004","unstructured":"Lincoln MJ, Brown SH, Nguyen V, Cromwell T, Carter J, Erlbaum M, et al. US Department of veterans affairs enterprise reference terminology strategic overview. Stud Health Technol Inform. 2004;107:391\u20135.","journal-title":"Stud Health Technol Inform."},{"issue":"Suppl.","key":"833_CR18","first-page":"898","volume":"33","author":"M Hayakawa","year":"2013","unstructured":"Hayakawa M, Imai T, Ohe K. Investigation of descriptions in open drug information databases toward adverse events reasoning system. Jpn J Med Inform. 2013;33(Suppl.):898\u2013901.","journal-title":"Jpn J Med Inform."},{"key":"833_CR19","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/clpt.2012.41","volume":"91","author":"PE Zhichkin","year":"2012","unstructured":"Zhichkin PE, Athey BD, Avigan MI, Abernethy DR. Needs for an expanded ontology-based classification of adverse drug reactions and related mechanisms. Clin. Pharmacol. Ther. 2012;91:963\u20135.","journal-title":"Clin. Pharmacol. Ther."},{"key":"833_CR20","unstructured":"Gene Ontology Consortium. Gene Ontology [Internet]. 1999.\u00a0\n                    http:\/\/geneontology.org\/\n                    \n                  . Accessed 8 Dec 2018."},{"key":"833_CR21","unstructured":"Foundational Model of Anatomy (FMA) [Internet]. 2019.\u00a0\n                    http:\/\/si.washington.edu\/projects\/fma\n                    \n                  . Accessed 18 May 2019."},{"key":"833_CR22","unstructured":"Imai T, Kou H, Zhou J, Kozaki K, Mizoguchi R, Ohe K. Japan Medical Ontology Development Project for Advanced Clinical. In: System Proceedings of 10th international HL7 interoperability conference 2009; 2009. p. 42\u20136."},{"key":"833_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13326-017-0132-2","volume":"8","author":"K Kozaki","year":"2017","unstructured":"Kozaki K, Yamagata Y, Mizoguchi R, Imai T, Ohe K. Disease compass\u2014a navigation system for disease knowledge based on ontology and linked data techniques. J Biomed Semant. 2017;8:1\u201318.","journal-title":"J Biomed Semant."},{"key":"#cr-split#-833_CR24.1","unstructured":"Imai T, Ohe K, Shinohara E, Kajino M, Sakurai R, Kozaki K, et al. An ontological framework for representing topological information in human anatomy. In: Proc international conference on biomedical ontology BioCreative (ICBO-BioCreative 2016), Corvallis, USA, August 1-4, 2016 CEUR Work Proceedings, vol. 1747"},{"key":"#cr-split#-833_CR24.2","unstructured":"2016. p. 3-8.   http:\/\/ceur-ws.org\/Vol-1747\/IT506_ICBO2016.pdf    . Accessed 8 Dec 2018."},{"key":"833_CR25","unstructured":"Mizoguchi R. YAMATO: Yet Another More Advanced Top-level Ontology [Internet]. 2016.\u00a0\n                    http:\/\/www.ei.sanken.osaka-u.ac.jp\/hozo\/onto_library\/upperOnto.htm\n                    \n                  . \u200bAccessed\u00a018 May 2019."},{"key":"833_CR26","first-page":"79","volume":"267","author":"S Borgo","year":"2014","unstructured":"Borgo S, Mizoguchi R. A first-order formalization of event, object, process and role in YAMATO. Front Artif Intell Appl. 2014;267:79\u201392.","journal-title":"Front Artif Intell Appl."},{"key":"833_CR27","unstructured":"Mizoguchi R. YAMATO: Yet Another More Advanced Top-level Ontology. In: Proceedings of sixth Australas ontology work Adelaide, Aust 7 December 2010; 2010. p. 1\u201316. \n                    https:\/\/pdfs.semanticscholar.org\/7117\/fa4b0fdaa737a90343ce8d4fcc890c57ea27.pdf\n                    \n                  . Accessed 8 Dec 2018."},{"key":"833_CR28","unstructured":"Mizoguchi R, Toyoshima F. YAMATO\u202f: Yet Another More Advanced Top-level Ontology with Analysis of Five Examples of Change. In: Proceedings of the jointt ontological work 2017, Bozen-Bolzano, Italy, Sept 2017, vol. 2050. p. 21\u201323. \n                    http:\/\/ceur-ws.org\/Vol-2050\/FOUST_paper_4.pdf\n                    \n                  . Accessed 8 Dec 2018."},{"key":"833_CR29","doi-asserted-by":"crossref","unstructured":"Kozaki K, Kitamura Y, Ikeda M, Mizoguchi R. Hozo: An environment for building\/using ontologies based on a fundamental consideration of \u201crole\u201d and \u201crelationship.\u201d Knowl Eng Knowl Manag Ontol Semant Web. 2002;213\u20138. \n                    https:\/\/link.springer.com\/chapter\/10.1007\/3-540-45810-7_21\n                    \n                  . Accessed 8 Dec 2018.","DOI":"10.1007\/3-540-45810-7_21"},{"key":"833_CR30","unstructured":"Mizoguchi R, Sunagawa E, Kozaki K, Kitamura Y. The model of roles within an ontology development tool: Hozo. Appl Ontol. 2007;2(2):159\u201379. \n                    https:\/\/content.iospress.com\/articles\/applied-ontology\/ao038\n                    \n                  . Accessed 8 Dec 2018."},{"key":"833_CR31","unstructured":"Kozaki K, Sunagawa E, Kitamura Y, Mizoguchi R. Role Representation model using OWL and SWRL. In: Proceedings of 2nd workshop on roles and relationships in object oriented programming, multiagent systems, and ontologies, Berlin, 30\u201331 July, p. 39\u201346, 2007. \n                    http:\/\/www.ei.sanken.osaka-u.ac.jp\/pub\/kozaki\/Role07kozaki.pdf\n                    \n                  . Accessed 8 Dec 2018."},{"key":"833_CR32","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/2041-1480-5-23","volume":"5","author":"Y Yamagata","year":"2014","unstructured":"Yamagata Y, Kozaki K, Imai T, Ohe K, Mizoguchi R. An ontological modeling approach for abnormal states and its application in the medical domain. J Biomed Semant. 2014;5:23.","journal-title":"J Biomed Semant"},{"key":"833_CR33","first-page":"567","volume":"192","author":"T Imai","year":"2013","unstructured":"Imai T, Hayakawa M, Ohe K. Development of description framework of pharmacodynamics ontology and its application to possible drug-drug interaction reasoning. Stud Health Technol Inf. 2013;192:567\u201371.","journal-title":"Stud Health Technol Inf."},{"key":"833_CR34","first-page":"178","volume-title":"Goodman and Gilman\u2019s the pharmacological basis of therapeutics","author":"LL Brunton","year":"2011","unstructured":"Brunton LL, Chabner BA. Goodman and Gilman\u2019s the pharmacological basis of therapeutics. New York: McGraw-Hill Prof. McGraw-Hill Professional; 2011. p. 178\u201380."},{"key":"833_CR35","first-page":"234","volume-title":"NEW pharmacology revised 6th edition","author":"C Tanaka","year":"2011","unstructured":"Tanaka C, Kato R. NEW pharmacology revised 6th edition. Nancodo: Tokyo; 2011. p. 234."},{"key":"833_CR36","volume-title":"Standard physiology revised 8th edition","author":"K Fukuda","year":"2014","unstructured":"Fukuda K. Standard physiology revised 8th edition. Tokyo: Igaku-shoin; 2014."},{"key":"833_CR37","unstructured":"The ICH MedDRA Management Committee Maintenance and Support Services Organization. MedDRA [Internet]. \n                    http:\/\/www.meddra.org\/\n                    \n                  . Accessed 18 May 2019."},{"key":"833_CR38","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","volume":"27","author":"EG Brown","year":"2004","unstructured":"Brown EG. Using MedDRA implications for risk management. Drug Saf. 2004;27:591\u2013602.","journal-title":"Drug Saf."},{"key":"833_CR39","unstructured":"Japan Pharmaceuticals and Medical Devices Agency of. Safety Alerts and Recalls\/Review Reports\/Package Inserts, etc [Internet]. 2013. \n                    http:\/\/www.pmda.go.jp\n                    \n                  . \u200bAccessed 20 May 2013."},{"key":"833_CR40","doi-asserted-by":"crossref","first-page":"117762501769607","DOI":"10.1177\/1177625017696075","volume":"11","author":"S Zaman","year":"2017","unstructured":"Zaman S, Sarntivijai S, Abernethy DR. Use of biomedical ontologies for integration of biological knowledge for learning and prediction of adverse drug reactions. Gene Regul Syst Biol. 2017;11:1177625017696075.","journal-title":"Gene Regul Syst Biol."},{"key":"833_CR41","unstructured":"Therapeutic target database [Internet]. 2018. \n                    http:\/\/bidd.nus.edu.sg\/group\/cjttd\/\n                    \n                  .\u00a0\u200bAccessed\u00a018 May 2019."},{"key":"833_CR42","doi-asserted-by":"publisher","first-page":"D1069","DOI":"10.1093\/nar\/gkv1230","volume":"44","author":"H Yang","year":"2016","unstructured":"Yang H, Qin C, Li YH, Tao L, Zhou J, Yu CY, et al. Therapeutic target database update 2016: Enriched resource for bench to clinical drug target and targeted pathway information. Nucleic Acids Res. 2016;44:D1069\u201374.","journal-title":"Nucleic Acids Res."},{"key":"833_CR43","unstructured":"STITCH Consortium. STITCH [Internet]. 2016. \n                    http:\/\/stitch.embl.de\/\n                    \n                  .\u00a0\u200bAccessed\u00a018 May 2019."},{"key":"833_CR44","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1093\/nar\/gkt1207","volume":"42","author":"M Kuhn","year":"2014","unstructured":"Kuhn M, Szklarczyk D, Pletscher-Frankild S, Blicher TH, Von Mering C, Jensen LJ, et al. STITCH 4: Integration of protein-chemical interactions with user data. Nucleic Acids Res. 2014;42:401\u20137.","journal-title":"Nucleic Acids Res."},{"key":"833_CR45","unstructured":"European Molecular Biology Laboratory. ChEMBL [Internet]. 2018. \n                    https:\/\/www.ebi.ac.uk\/chembl\/\n                    \n                  .\u00a0\u200bAccessed\u00a018 May 2019."},{"key":"833_CR46","doi-asserted-by":"publisher","first-page":"D945","DOI":"10.1093\/nar\/gkw1074","volume":"45","author":"A Gaulton","year":"2017","unstructured":"Gaulton A, Hersey A, Nowotka ML, Patricia Bento A, Chambers J, Mendez D, et al. The ChEMBL database in 2017. Nucleic Acids Res. 2017;45:D945\u201354.","journal-title":"Nucleic Acids Res."},{"key":"833_CR47","unstructured":"EMBL-EBI. ChEBI [Internet]. 2018. \n                    http:\/\/www.ebi.ac.uk\/chebi\/\n                    \n                  .\u00a0\u200bAccessed\u00a018 May 2019."},{"key":"833_CR48","doi-asserted-by":"publisher","first-page":"D344","DOI":"10.1093\/nar\/gkm791","volume":"36","author":"K Degtyarenko","year":"2008","unstructured":"Degtyarenko K, de Matos P, Ennis M, Hastings J, Zbinden M, McNaught A, et al. ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 2008;36:D344\u201350.","journal-title":"Nucleic Acids Res."},{"key":"833_CR49","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nature11159","volume":"486","author":"E Lounkine","year":"2012","unstructured":"Lounkine E, Keiser MJ, Whitebread S, Mikhailov D, Hamon J, Jenkins JL, et al. Large-scale prediction and testing of drug activity on side-effect targets. Nature. 2012;486:361\u20137.","journal-title":"Nature."},{"key":"833_CR50","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1136\/amiajnl-2012-000933","volume":"20","author":"P Avillach","year":"2013","unstructured":"Avillach P, Coloma PM, Gini R, Schuemie M, Mougin F, Dufour J-C, et al. Harmonization process for the identification of medical events in eight European healthcare databases: the experience from the EU-ADR project. J Am Med Inf Assoc. 2013;20:184\u201392.","journal-title":"J Am Med Inf Assoc."},{"key":"833_CR51","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jbi.2013.10.008","volume":"47","author":"R Xu","year":"2014","unstructured":"Xu R, Wang Q. Automatic signal extraction, prioritizing and filtering approaches in detecting post-marketing cardiovascular events associated with targeted cancer drugs from the FDA Adverse Event Reporting System (FAERS). J Biomed Inform. 2014;47:171\u20137.","journal-title":"J Biomed Inform."},{"key":"833_CR52","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.drudis.2012.08.005","volume":"18","author":"Z Liu","year":"2013","unstructured":"Liu Z, Fang H, Reagan K, Xu X, Mendrick DL, Slikker W, et al. In silico drug repositioning: what we need to know. Drug Discov Today. 2013;18:110\u20135.","journal-title":"Drug Discov Today"},{"key":"833_CR53","doi-asserted-by":"publisher","first-page":"e89324","DOI":"10.1371\/journal.pone.0089324","volume":"9","author":"K Jung","year":"2014","unstructured":"Jung K, LePendu P, Chen WS, Iyer SV, Readhead B, Dudley JT, et al. Automated detection of off-label drug use. PLoS One. 2014;9:e89324.","journal-title":"PLoS One."},{"key":"833_CR54","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1038\/nbt1338","volume":"25","author":"MA Yildirim","year":"2007","unstructured":"Yildirim MA, Goh K-I, Cusick ME, Barab\u00e1si A-L, Vidal M. Drug-target network. Nat Biotechnol. 2007;25:1119\u201326.","journal-title":"Nat Biotechnol."},{"key":"833_CR55","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.pharmthera.2009.10.011","volume":"125","author":"A Hisaka","year":"2010","unstructured":"Hisaka A, Ohno Y, Yamamoto T, Suzuki H. Prediction of pharmacokinetic drug-drug interaction caused by changes in cytochrome P450 activity using in vivo information. Pharmacol Ther. 2010;125:230\u201348.","journal-title":"Pharmacol Ther."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-019-00833-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-019-00833-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-019-00833-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T23:37:45Z","timestamp":1590017865000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-019-00833-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,22]]},"references-count":56,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["833"],"URL":"https:\/\/doi.org\/10.1007\/s40264-019-00833-2","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"type":"print","value":"0114-5916"},{"type":"electronic","value":"1179-1942"}],"subject":[],"published":{"date-parts":[[2019,5,22]]},"assertion":[{"value":"22 May 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This manuscript does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Masayo Hayakawa, Takeshi Imai, Yoshimasa Kawazoe, Kouji Kozaki, and Kazuhiko Ohe have no conflicts of interest that are directly relevant to the content of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This work was partially supported by Health, Labour and Welfare Sciences Research Grants number H28-IRYO-SHITEI-020, Japan, and JSPS KAKENHI Grant number JP26460857.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}